Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Shanghai Pharmaceuticals Holding Co ( (HK:2607) ) just unveiled an announcement.
Shanghai Pharmaceuticals Holding Co., Ltd. has released its third quarterly report for 2025, prepared in accordance with PRC Accounting Standards for Business Enterprises. The report, which has not been audited, emphasizes the company’s commitment to transparency and accuracy in its financial disclosures, as affirmed by its board of directors and senior management. This announcement underscores the company’s adherence to regulatory requirements and its ongoing efforts to maintain trust with stakeholders.
The most recent analyst rating on (HK:2607) stock is a Buy with a HK$13.50 price target. To see the full list of analyst forecasts on Shanghai Pharmaceuticals Holding Co stock, see the HK:2607 Stock Forecast page.
More about Shanghai Pharmaceuticals Holding Co
Shanghai Pharmaceuticals Holding Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating in the pharmaceutical industry. The company is primarily engaged in the development, manufacturing, and distribution of pharmaceutical products, with a focus on the Chinese market.
Average Trading Volume: 3,259,649
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$77.57B
For a thorough assessment of 2607 stock, go to TipRanks’ Stock Analysis page.